Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1993-8-5
|
pubmed:abstractText |
Tin mesoporphyrin (SnMP) is a competitive inhibitor of heme oxygenase being examined clinically for the treatment of hyperbilirubinemia. Since liposomes have been shown to target SnMP to the spleen and increase its efficacy (S. A. Landaw, G. S. Drummond, and A. Kappas, Pediatrics 84, 1091-1096, 1989), we began investigating the feasibility of the preparation and scaleup of a liposomal SnMP formulation for clinical use. SnMP liposomes were prepared by high-pressure homogenization of a suspension of SnMP and egg phosphatidylcholine (1:20, w/w) in lactose-phosphate buffer, resulting in SnMP liposomes that were less than 200 nm in diameter and had encapsulation efficiencies of up to 90% at pH 5. The SnMP liposomes could be sterile filtered and lyophilized in a 1-day cycle with retention of the encapsulation efficiency and particle size. Following injection into rats, the distribution of liposomal SnMP to spleen at 2 and 6 hr after dosing was 5-20 times higher than for aqueous SnMP. Lyophilized SnMP liposomes were also more effective than aqueous SnMP in decreasing bilirubin production in bile-cannulated rats. The results suggest the potential for producing a safe, sterile, and effective lyophilized formulation of SnMP liposomes for targeting of heme oxygenase inhibitors to the spleen.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bilirubin,
http://linkedlifedata.com/resource/pubmed/chemical/Buffers,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Heme Oxygenase (Decyclizing),
http://linkedlifedata.com/resource/pubmed/chemical/Liposomes,
http://linkedlifedata.com/resource/pubmed/chemical/Metalloporphyrins,
http://linkedlifedata.com/resource/pubmed/chemical/tin mesoporphyrin
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0724-8741
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
715-21
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8321837-Animals,
pubmed-meshheading:8321837-Bilirubin,
pubmed-meshheading:8321837-Buffers,
pubmed-meshheading:8321837-Drug Carriers,
pubmed-meshheading:8321837-Freeze Drying,
pubmed-meshheading:8321837-Heme Oxygenase (Decyclizing),
pubmed-meshheading:8321837-Hydrogen-Ion Concentration,
pubmed-meshheading:8321837-Liposomes,
pubmed-meshheading:8321837-Metalloporphyrins,
pubmed-meshheading:8321837-Rats,
pubmed-meshheading:8321837-Spleen,
pubmed-meshheading:8321837-Tissue Distribution
|
pubmed:year |
1993
|
pubmed:articleTitle |
Targeted delivery of a heme oxygenase inhibitor with a lyophilized liposomal tin mesoporphyrin formulation.
|
pubmed:affiliation |
Abbott Laboratories, North Chicago, Illinois 60064.
|
pubmed:publicationType |
Journal Article
|